Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer

The study will use T cells from healthy donors, modified using a novel universal CAR-T technology, to treat metastatic colorectal cancer patients. The antigen-binding site of the CAR molecule recognizes GCC as the target. The main questions it aims to answer are: * What is the maximum tolerated dose (MTD) of GCC-CAR-T therapy in universal CAR-T cell treatments? * What are the dose-limiting toxicities (DLT) and treatment-emergent adverse events (TEAE)? * What is the treatment\'s efficacy, as measured by objective response rate (ORR) and progression-free survival (PFS)? Researchers will assess whether universal CAR-T cells have good safety and efficacy in treating colorectal cancer, while improving accessibility and lowering treatment costs. Participants will: * Receive universal GCC-CAR-T cells through a 3+3 dose escalation scheme. * Undergo chemotherapy conditioning before CAR-T infusion. * Be monitored for adverse events, immune response, and disease progression. The study will collect data on both short-term outcomes (within the first few months post-treatment) and long-term safety and efficacy.